<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02079727</url>
  </required_header>
  <id_info>
    <org_study_id>12EU/Ct06</org_study_id>
    <secondary_id>2013-001619-62</secondary_id>
    <nct_id>NCT02079727</nct_id>
  </id_info>
  <brief_title>Condrosulf vs Celebrex vs Placebo in the Treatment of Knee OA</brief_title>
  <official_title>A Multicentre, Comparative, Randomised, Double-blind, Double-dummy Clinical Trial on the Efficacy and Safety of Condrosulf Versus Celebrex and Versus a Placebo in the Treatment of Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IBSA Institut Biochimique SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IBSA Institut Biochimique SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the efficacy and safety of 800 mg Chondroitin 4&amp;6
      sulfate (Condrosulf) vs placebo once a day for 6 months in the symptomatic treatment of knee
      osteoarthritis. A third group, Celecoxib 200 mg (Celebrex) once a day, will be used as active
      comparator.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 12, 2014</start_date>
  <completion_date type="Actual">June 16, 2016</completion_date>
  <primary_completion_date type="Actual">October 19, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lequesne's Index</measure>
    <time_frame>Day 1 and Day 182</time_frame>
    <description>Decrease in the scores of the Lequesne's Index from Day 1 to Day 182.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain (VAS in mm)</measure>
    <time_frame>Day 1 and Day 182</time_frame>
    <description>Decrease in the VAS (pain in mm) from Day 1 to Day 182</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lequesne's Index</measure>
    <time_frame>Day 1, 30, 90 and 182</time_frame>
    <description>Evolution from Day 1 to Day 30, Day 90 and Day 182</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain (VAS in mm)</measure>
    <time_frame>Day 1, 30, 91 and 182</time_frame>
    <description>Evolution of the pain on VAS (in mm) from Day 1 to Day 30, Day 91 and Day 182</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MCII (minimal clinically important improvement)</measure>
    <time_frame>Day 1, 30, 91 and 182</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PASS (patient acceptable symptom state)</measure>
    <time_frame>Day 1, 30, 91 and 182</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of Paracetamol</measure>
    <time_frame>Day 1, 30, 91 and 182</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global efficacy assessment</measure>
    <time_frame>At Day 30, 91 and 182</time_frame>
    <description>Global efficacy assessed by the patient and the Investigator by means of a semi-quantitative verbal scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events related to the treatments</measure>
    <time_frame>At Day 30, 91 and 182</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of drop-outs due to AE (adverse event) related to the treatment</measure>
    <time_frame>At Day 30, 91 and 182</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Treatment compliance</measure>
    <time_frame>Day 1, 30, 91 and 182</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">604</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Condrosulf (Chondroitin 4&amp;6 sulfate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet of Condrosulf 800 mg and 1 capsule of placebo of Celebrex once a day for 182 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (PBO) 800 mg tablet and Placebo (PBO) 200 mg capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 tablet of PBO of Condrosulf and 1 capsule of PBO of Celebrex, once a day for 182 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celebrex 200 mg capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 capsule of 200 mg of Celebrex and 1 tablet of 800 mg placebo of Condrosulf once a day for 182 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chondroitin sulfate</intervention_name>
    <arm_group_label>Condrosulf (Chondroitin 4&amp;6 sulfate)</arm_group_label>
    <other_name>Condrosulf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
    <arm_group_label>Celebrex 200 mg capsule</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo (PBO) 800 mg tablet and Placebo (PBO) 200 mg capsule</arm_group_label>
    <other_name>placebo for chondroitin sulfate and placebo for celecoxib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients of either sex, aged ≥50 years

          -  Patients affected by primary knee osteoarthritis of the medial or lateral
             femoro-tibial compartment

          -  Diagnosis according to the American College of Rheumatology (ACR) criteria

          -  Kellgren &amp; Lawrence grade I-III

          -  Knee osteoarthritis evolving for more than 6 months

          -  Patients suffering from regular pain and functional disorders from at least 3 months

          -  Accomplishing a score ≥ 7 of Lequesne's index for the knee osteoarthritis

          -  Assessing pain on Huskisson's VAS ≥ 50 mm

          -  With radiography dated less than six months showing a remaining articular joint space

          -  Without such an axial disorder to justify an osteotomy

          -  Women taking contraceptive measures if not in menopause

          -  Women having negative pregnancy test

          -  Patients able to understand and follow the study protocol

          -  Patients who have signed the written informed consent for their participation in the
             clinical trial

        Exclusion Criteria:

          -  With a history of heart attack, ischemic heart disease or cerebrovascular disease
             (including transient ischemic attacks)

          -  Having or have had peripheral arterial disease or past surgery orf peripheral arteries

          -  With a history or currently significat coagulation defect or/and blood dyscrasia

          -  With high risk of cardiovascular events

          -  With any acute or chronic infections requiring antimicrobial therapy or serious viral
             (e.g., hepatitis, HIV positivity) or fungal infections

          -  With a history of recurrent gastrointestinal ulceration or active inflammatory bowel
             diseases (e.g., Crohn's disease or ulcerative colitis)

          -  Having been diagnosed as having or have been treated for oesophageal, gastric, pyloric
             channel, or duodenal ulceration within 30 days prior to receiving the first dose of
             study medication

          -  Having severe liver or kidney disease

          -  With allergy to Celebrex or any of the other ingredients of Celebrex

          -  Having had an allergic reaction to sulphonamides

          -  Having had, as a result of intake of acetylsalicylic acid or other NSAIDs, asthma,
             nose polyps, severe nose congestion, or an allergic reaction such as itchy skin rash,
             swelling of the face, lips, tongue or throat, breathing difficulties or wheezing

          -  Presenting lactose intolerance

          -  Mild or not symptomatic knee osteoarthritis : &lt; 7 of Lequesne's index,

          -  Pain on Huskisson's VAS (Visual Analogic Scale) &lt; 50 mm

          -  Predominantly femoro-patellar osteoarthritis

          -  Destructive osteoarthritis of the knee justifying a surgery in the following 6 months

          -  Osteoarthritis with hydrarthrosis requiring a puncture or an infiltration

          -  Important genu varum or valgus &gt;8° (physiological angle including)

          -  Kellgren &amp; Lawrence grade IV

          -  Knee joint surgery in the last 3 months (e.g. chondroscopy, arthroscopy)

          -  Viscosupplementation, tidal lavage in the last 6 months

          -  Arthritis and metabolic arthropathies, Paget's illness

          -  Having consumed: basic treatment of arthritis with SYSADOA, symptomatic slow acting
             drugs for osteoarthrithis (chondroitin sulphates, glucosamine sulphates, diacerhein,
             hyaluronic acid and food supplement for joint care) in the last 3 months; treatment
             with corticoids, by any administration route during the last month; any medication
             having an influence on pain:

          -  NSAIDs (nonsteroidal anti-inflammatory drugs) in the 5 days preceding the inclusion
             (wash-out period considering 5 half-lives of the drug)

          -  hypnotics, muscle relaxants, anxiolytics, if the intake has started less than 8 days
             before inclusion

          -  paracetamol in the 10 hours preceding the inclusion

          -  Foreseen physiotherapy, re-education, alternative medicine (mesotherapy, acupuncture)
             in the next six months (study period)

          -  Presenting psychiatric illness hindering the protocol complaince, alcoholism, ongoing
             or &lt; 1 year drug dependency

          -  Pregnant or likely to become it during clinical trial or lactating

          -  Women having positive pregnancy test

          -  Having participated in other clinical trials in the month preceding the clinical
             trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Yves Reginster, Prof. MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unité d'Exploration du Métabolisme Osseux, CHU Centre ville, Polycliniques Universitaires L-Brull, Liège, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unité d'exploration du metabolism osseux, CHU, Polyclinique universitaires L-Brull</name>
      <address>
        <city>Liege</city>
        <zip>4020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interni a revmatologicka ordinace</name>
      <address>
        <city>Breclav</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ortopedicka Ambulance</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vesalion s.r.o.</name>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomayerova nemocnice - Revmatologicke a rehabilitacne oddeleni</name>
      <address>
        <city>Praha - Krc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicky ustav</name>
      <address>
        <city>Praha 2</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Plus</name>
      <address>
        <city>Uherske Hradiste</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Osp. Univ. Di Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Zdrowej Kosci</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lubelskie Centrum Diagnostyczne</name>
      <address>
        <city>Swidnik</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SOLB</name>
      <address>
        <city>ul. Jana III Sobieskiego</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medica Pro Familia</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zdrowie Osteo-Medic</name>
      <address>
        <city>Wiejska</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethesda-Spital</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HFR Fribourg - Hôpital Cantonal</name>
      <address>
        <city>Fribourg</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich, Rheumaklinik</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2014</study_first_submitted>
  <study_first_submitted_qc>March 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2014</study_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Condrosulf</keyword>
  <keyword>Chondroitin sulfate</keyword>
  <keyword>Celebrex</keyword>
  <keyword>Knee OA</keyword>
  <keyword>Knee osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

